SANION (SANION) News
Follow SANION (SANION) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Saniona (SANION) Completes Tox and CMC for SAN2465, Targets IND by Oct 2026
Saniona completed toxicology and CMC work for SAN2465 and expects to submit an IND to the FDA by the end of October 2026. A Phase 1 study in healthy volunteers is planned.Material DetailsContext by AI AnalystThis is an e
REGULATION | Sep 24, 2026, 06:01 AM UTC
L
Saniona (Q2 review): With focus into the clinic
Redeye’s analyst just published a Research Update on Saniona.Click here to read the articleMake sure to add Saniona to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your
EQUITY | Sep 07, 2026, 04:01 PM UTC
M
Saniona advances two internal programs toward clinic around year-end
Saniona says SAN2668 for severe pediatric epilepsy and SAN2465 for major depressive disorder are targeting phase I initiation around year-end, alongside a partnership portfolio expected to generate cash to support them.
EQUITY | Sep 01, 2026, 01:20 PM UTC
M
Saniona Q2 2026 revenue down to SEK 4.5 million
Saniona reports Q2 2026 revenue down to SEK 4.5 million.
EQUITY | Aug 27, 2026, 06:09 AM UTC
L
Sanion widened losses, lower revenue offset by cash and $5M AstronauTx income
Sanion reported widened losses and lower revenue, offset by strong cash reserves and new $5M AstronauTx income.
EARNINGS | Aug 27, 2026, 06:02 AM UTC
L
Saniona publishes Q2 2026 interim report
Saniona has published its interim report for the second quarter of 2026.
EQUITY | Aug 27, 2026, 06:01 AM UTC